Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 5/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033806 | 0.87 | SMN1; SMN2 (0.53) | PYCR1HDAC6HDAC3ACHEBCHE | |
| SCHEMBL14691675 | 0.76 | TDP1 (0.58) | HDAC6HDAC3TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL10033811 | 0.76 | PYCR1 (0.60) | PYCR1HDAC6HDAC3ACHESMN1; SMN2 | |
| SCHEMBL14691673 | 0.76 | TDP1 (0.58) | HDAC6HDAC3TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL10033812 | 0.74 | PYCR1 (0.48) | PYCR1ACHEHDAC1 | |
| SCHEMBL10033790 | 0.71 | PYCR1 (0.53) | PYCR1ACHESMN1; SMN2MAOAMAOB | |
| SCHEMBL14125425 | 0.69 | PYCR1 (0.56) | PYCR1ACHESMN1; SMN2MAOAMAOB | |
| SCHEMBL10033800 | 0.68 | RAB9A (0.53) | PYCR1SMN1; SMN2MAOAMAOBRAB9A | |
| SCHEMBL23054865 | 0.68 | HDAC3 (0.75) | HDAC6HDAC3ACHEBCHEMAOA | |
| SCHEMBL28479289 | 0.68 | SMN1; SMN2 (0.59) | TAS1R3TAS1R1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | MAOA, MAOB, PNMT | PYCR1 975/4885HDAC6 306/4885HDAC3 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.